Instituto Medico Alexander Fleming (Site 0578)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Bladder cancer

Closed trials

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source